NEW YORK, May 22, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (OTCQB:TYMI), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today announced that it will present data from its ongoing clinical trial with its investigational drug candidate SM-88 in prostate cancer at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 2 – 6, 2017.
Details of the Company’s poster presentation are listed below:
A Phase Ib/II, Open-label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of SM-88 in Patients with Prostate Cancer (J Clin Oncol 35, 2017 (suppl; abstr TPS2615))
Poster Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Date and Time: Monday June 5, 2017, 8:00 AM - 11:30 AM CT
Location: Hall A, Poster Board: #97b
Presenter: Dr. Giuseppe Del Priore, Chief Medical Officer of Tyme Technologies, Inc.
Additionally, the following abstracts have been published online in conjunction with the Meeting and are available for review via the hyperlinks below.
SMK/SM-88 Toxicity, Efficacy, and Patient Reported Outcomes in Metastatic Pancreas Cancer
Author(s): Steve Hoffman, Jeanetta Stega, Giuseppe Del Priore, John Rothman; Tyme Inc, New York, NY; Morehouse School of Medicine, Atlanta, GA. J Clin Oncol 35, 2017 (suppl; abstr e14060).
SM-88/SMK Non-hormonal Therapy in Recurrent or Untreated Prostate Cancer
Author(s): Steve Hoffman, John Rothman, Giuseppe Del Priore, Jeanetta Stega; Tyme Inc, New York, NY; Morehouse School of Medicine, Atlanta, GA. J Clin Oncol 35, 2017 (suppl; abstr e16540).
SM-88 in Non-metastatic Rising PSA-recurrent Prostate Cancer
Author(s): Giuseppe Del Priore, Gerald H. Sokol, Wen-Tien Chen, Che-Kai Tsao, Steve Hoffman; Morehouse School of Medicine, Atlanta, GA; Florida Cancer Institute New Hope, Hudson, FL; Stony Brook University, Stony Brook, NY; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; Tyme Inc, New York, NY. J Clin Oncol 35, 2017 (suppl; abstr e16567).
Phase Ib Pharmacokinetics of Non-hormonal SM-88 in Patients with Non-metastatic Recurrent Prostate Cancer
Author(s): Giuseppe Del Priore, John Rothman, Gerald H. Sokol, Karen Hoffman, Avi S. Retter, Steve Hoffman; Morehouse School of Medicine, Atlanta, GA; Tyme Inc, New York, NY; Florida Cancer Institute New Hope, Hudson, FL; Eastchester Center for Cancer Care, Bronx, NY; Montefiore Medical Center, Bronx, NY. J Clin Oncol 35, 2017 (suppl; abstr e14061).
Tyme Technologies is a clinical-stage biopharmaceutical company focused on development and commercialization of highly targeted cancer therapeutics with a broad range of oncology indications. Its lead investigational candidate, SM-88, is a novel first-in-class therapy that is designed to use cancer’s unusual metabolism to selectively break down the cellular defenses of tumors, leading to tumor cell death. Through clinical trials and expanded access programs, SM-88 has been used in over 84 individuals and shown a clinical response in thirteen cancer types. In its first-in-human trial for end-stage, metastatic cancer patients, SM-88 treatment resulted in a median overall survival of 26 months, with 32% of patients alive at the end of the three-year evaluation period without any drug-related serious adverse events. The Company is currently conducting a Phase II trial in prostate cancer in addition to ongoing collaborations with the Mayo Clinic, Mount Sinai and other institutions. For more information, visit our website: www.tymeinc.com.
Forward-Looking Statements/Disclosure Notice
In addition to historical information, this press release contains forward-looking statements that involve substantial risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding our drug candidates (including SM-88), our drug development plans and strategies, our completed and planned clinical trials and the therapeutic design and mechanisms of our drug candidates; and readers can identify forward-looking statements by sentences or passages involving the use of terms such as “anticipates,” “believes,” “designed,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of Tyme’s control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties inherent in research and development, including the ability to achieve clinical study start and completion dates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final Phase II data analysis, final results of additional clinical trials, or both, may be different from the preliminary data analysis and may not support further clinical development; whether and when any applications or other submissions for SM-88 may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88; competitive developments; and the factors described in the section captioned “Risk Factors” of Tyme’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 30, 2016 (available at www.sec.gov).
The information contained in this press release is as of May 22, 2017 and Tyme assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.
CONTACT: Contacts ICR Healthcare Media / Investors James Heins / Stephanie Carrington Tel: +1 203 682 8251 Tel: +1 646 277 1282 Email: James.Heins@icrinc.com Email: Stephanie.Carrington@icrinc.com